Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127


CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL.

Clin Cancer Res. 2019 Apr 15;25(8):2560-2574. doi: 10.1158/1078-0432.CCR-18-0432. Epub 2019 Jan 17.


Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer.

Moore PA, Shah K, Yang Y, Alderson R, Roberts P, Long V, Liu D, Li JC, Burke S, Ciccarone V, Li H, Fieger CB, Hooley J, Easton A, Licea M, Gorlatov S, King KL, Young P, Adami A, Loo D, Chichili GR, Liu L, Smith DH, Brown JG, Chen FZ, Koenig S, Mather J, Bonvini E, Johnson S.

Mol Cancer Ther. 2018 Aug;17(8):1761-1772. doi: 10.1158/1535-7163.MCT-17-1086. Epub 2018 Jun 4.


Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R, Gottardi D, Massaia M, Giacomo FD, Guarini AR, Foà R, Kyriakides PW, Bareja R, Elemento O, Chichili GR, Monteleone E, Moore PA, Johnson S, Bonvini E, Cignetti A, Inghirami G.

Oncoimmunology. 2018 Feb 8;7(4):e1341032. doi: 10.1080/2162402X.2017.1341032. eCollection 2018.


Effects of feeding low fishmeal diets with increasing soybean meal levels on growth, gut histology and plasma biochemistry of sea bass.

Bonvini E, Bonaldo A, Mandrioli L, Sirri R, Dondi F, Bianco C, Fontanillas R, Mongile F, Gatta PP, Parma L.

Animal. 2018 May;12(5):923-930. doi: 10.1017/S1751731117002683. Epub 2017 Oct 17.


MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies.

Liu L, Lam CK, Long V, Widjaja L, Yang Y, Li H, Jin L, Burke S, Gorlatov S, Brown J, Alderson R, Lewis MD, Nordstrom JL, Koenig S, Moore PA, Johnson S, Bonvini E.

Clin Cancer Res. 2017 Mar 15;23(6):1506-1518. doi: 10.1158/1078-0432.CCR-16-0666. Epub 2016 Sep 23.


Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.

Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, Jin M, O'Sullivan C, Cummins E, Lambert M, Sheehan AD, Ma W, Gatto S, Kerns K, Lam K, D'Antona AM, Zhu L, Brady WA, Benard S, King A, He T, Racie L, Arai M, Barrett D, Stochaj W, LaVallie ER, Apgar JR, Svenson K, Mosyak L, Yang Y, Chichili GR, Liu L, Li H, Burke S, Johnson S, Alderson R, Finlay WJJ, Lin L, Olland S, Somers W, Bonvini E, Gerber HP, May C, Moore PA, Tchistiakova L, Bloom L.

Antibodies (Basel). 2016 Mar 4;5(1). pii: E6. doi: 10.3390/antib5010006.


Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L, DiPersio JF.

Blood. 2016 Jan 7;127(1):122-31. doi: 10.1182/blood-2014-05-575704. Epub 2015 Nov 3.


A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.

Chichili GR, Huang L, Li H, Burke S, He L, Tang Q, Jin L, Gorlatov S, Ciccarone V, Chen F, Koenig S, Shannon M, Alderson R, Moore PA, Johnson S, Bonvini E.

Sci Transl Med. 2015 May 27;7(289):289ra82. doi: 10.1126/scitranslmed.aaa5693.


Fatty acid composition of eggs and its relationships to egg and larval viability from domesticated common sole (Solea solea) breeders.

Parma L, Bonaldo A, Pirini M, Viroli C, Parmeggiani A, Bonvini E, Gatta PP.

Reprod Domest Anim. 2015 Apr;50(2):186-194. doi: 10.1111/rda.12466. Epub 2014 Dec 4.


Isolation of cancer stem like cells from human adenosquamous carcinoma of the lung supports a monoclonal origin from a multipotential tissue stem cell.

Mather JP, Roberts PE, Pan Z, Chen F, Hooley J, Young P, Xu X, Smith DH, Easton A, Li P, Bonvini E, Koenig S, Moore PA.

PLoS One. 2013 Dec 4;8(12):e79456. doi: 10.1371/journal.pone.0079456. eCollection 2013.


Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J; Protégé Trial Investigators.

Diabetes. 2013 Nov;62(11):3901-8. doi: 10.2337/db13-0236. Epub 2013 Jun 25.


C-reactive protein causes insulin resistance in mice through Fcγ receptor IIB-mediated inhibition of skeletal muscle glucose delivery.

Tanigaki K, Vongpatanasin W, Barrera JA, Atochin DN, Huang PL, Bonvini E, Shaul PW, Mineo C.

Diabetes. 2013 Mar;62(3):721-31. doi: 10.2337/db12-0133. Epub 2012 Oct 15.


Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.

Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton AN, Li JC, Rillema JR, Licea M, Fieger C, Liang TW, Mather JP, Koenig S, Stewart SJ, Johnson S, Bonvini E, Moore PA.

Clin Cancer Res. 2012 Jul 15;18(14):3834-45. doi: 10.1158/1078-0432.CCR-12-0715. Epub 2012 May 21.


Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.

Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E.

Breast Cancer Res. 2011;13(6):R123. doi: 10.1186/bcr3069. Epub 2011 Nov 30.


Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.

Flaherty MM, MacLachlan TK, Troutt M, Magee T, Tuaillon N, Johnson S, Stein KE, Bonvini E, Garman R, Andrews L.

Toxicol Sci. 2012 Jan;125(1):299-309. doi: 10.1093/toxsci/kfr278. Epub 2011 Oct 24.


Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators.

Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.


Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.

Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, Shah K, Jin L, Zhang S, He L, Zhang T, Ciccarone V, Koenig S, Bonvini E, Johnson S.

Blood. 2011 Apr 28;117(17):4542-51. doi: 10.1182/blood-2010-09-306449. Epub 2011 Feb 7.


Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.

Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, Rainey GJ, Ciccarone V, Zhang T, Shah K, Jin L, Ning L, Minor T, Moore PA, Koenig S, Johnson S, Bonvini E.

Arthritis Rheum. 2010 Jul;62(7):1933-43. doi: 10.1002/art.27477.


Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, Yang Y, Jin L, Ciccarone V, Moore PA, Koenig S, Bonvini E.

J Mol Biol. 2010 Jun 11;399(3):436-49. doi: 10.1016/j.jmb.2010.04.001. Epub 2010 Apr 9.


IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.

Cady CT, Powell MS, Harbeck RJ, Giclas PC, Murphy JR, Katial RK, Weber RW, Hogarth PM, Johnson S, Bonvini E, Koenig S, Cambier JC.

Immunol Lett. 2010 May 4;130(1-2):57-65. doi: 10.1016/j.imlet.2009.12.001. Epub 2009 Dec 30.


The inhibitory Fc gamma IIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease.

Wenink MH, Santegoets KC, Roelofs MF, Huijbens R, Koenen HJ, van Beek R, Joosten I, Meyer-Wentrup F, Mathsson L, Ronnelid J, Adema GJ, Bonvini E, Koenig S, van den Berg WB, van Riel PL, Radstake TR.

J Immunol. 2009 Oct 1;183(7):4509-20. doi: 10.4049/jimmunol.0900153. Epub 2009 Sep 4.


C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1.

Tanigaki K, Mineo C, Yuhanna IS, Chambliss KL, Quon MJ, Bonvini E, Shaul PW.

Circ Res. 2009 Jun 5;104(11):1275-82. doi: 10.1161/CIRCRESAHA.108.192906. Epub 2009 May 7.


CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.

Zhou P, Comenzo RL, Olshen AB, Bonvini E, Koenig S, Maslak PG, Fleisher M, Hoffman J, Jhanwar S, Young JW, Nimer SD, Boruchov AM.

Blood. 2008 Apr 1;111(7):3403-6. doi: 10.1182/blood-2007-11-125526. Epub 2008 Jan 23.


Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Koenig S, Bonvini E.

Adv Enzyme Regul. 2008;48:152-64. doi: 10.1016/j.advenzreg.2007.11.011. Epub 2007 Dec 3. No abstract available.


Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.

Cancer Res. 2007 Sep 15;67(18):8882-90. Erratum in: Cancer Res. 2008 Sep 15;68(18):7692. Vijh, Sujata [added].


Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.

Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S.

Immunology. 2007 Jul;121(3):392-404. Epub 2007 Mar 26.


The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis.

Radstake TR, Franke B, Wenink MH, Nabbe KC, Coenen MJ, Welsing P, Bonvini E, Koenig S, van den Berg WB, Barrera P, van Riel PL.

Arthritis Rheum. 2006 Dec;54(12):3828-37.


Intramolecular regulation of phospholipase C-gamma1 by its C-terminal Src homology 2 domain.

DeBell K, Graham L, Reischl I, Serrano C, Bonvini E, Rellahan B.

Mol Cell Biol. 2007 Feb;27(3):854-63. Epub 2006 Nov 20.


Bayesian decision procedures for binary and continuous bivariate dose-escalation studies.

Zhou Y, Whitehead J, Bonvini E, Stevens JW.

Pharm Stat. 2006 Apr-Jun;5(2):125-33.


CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.

Rankin CT, Veri MC, Gorlatov S, Tuaillon N, Burke S, Huang L, Inzunza HD, Li H, Thomas S, Johnson S, Stavenhagen J, Koenig S, Bonvini E.

Blood. 2006 Oct 1;108(7):2384-91. Epub 2006 Jun 6.


Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.

Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW.

J Clin Invest. 2005 Oct;115(10):2914-23. Epub 2005 Sep 15.


A new tyrosine phosphorylation site in PLC gamma 1: the role of tyrosine 775 in immune receptor signaling.

Serrano CJ, Graham L, DeBell K, Rawat R, Veri MC, Bonvini E, Rellahan BL, Reischl IG.

J Immunol. 2005 May 15;174(10):6233-7.


Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells.

Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, Steinman RM, Ravetch JV, Dhodapkar MV.

Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2910-5. Epub 2005 Feb 9.


dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats.

Baladrón V, Ruiz-Hidalgo MJ, Nueda ML, Díaz-Guerra MJ, García-Ramírez JJ, Bonvini E, Gubina E, Laborda J.

Exp Cell Res. 2005 Feb 15;303(2):343-59. Epub 2004 Nov 2.


Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design.

Lachenbruch PA, Rosenberg AS, Bonvini E, Cavaillé-Coll MW, Colvin RB.

Am J Transplant. 2004 Apr;4(4):451-7. Review.


A dynamic constitutive and inducible binding of c-Cbl by PLCgamma1 SH3 and SH2 domains (negatively) regulates antigen receptor-induced PLCgamma1 activation in lymphocytes.

Rellahan BL, Graham LJ, Tysgankov AY, DeBell KE, Veri MC, Noviello C, Bonvini E.

Exp Cell Res. 2003 Sep 10;289(1):184-94.


On the mechanism coupling phospholipase Cgamma1 to the B- and T-cell antigen receptors.

Bonvini E, DeBell KE, Verí MC, Graham L, Stoica B, Laborda J, Aman MJ, DiBaldassarre A, Miscia S, Rellahan BL.

Adv Enzyme Regul. 2003;43:245-69. Review. No abstract available.


70Z/3 Cbl induces PLC gamma 1 activation in T lymphocytes via an alternate Lat- and Slp-76-independent signaling mechanism.

Graham LJ, Verí MC, DeBell KE, Noviello C, Rawat R, Jen S, Bonvini E, Rellahan B.

Oncogene. 2003 Apr 24;22(16):2493-503.


The EGF-like homeotic protein dlk affects cell growth and interacts with growth-modulating molecules in the yeast two-hybrid system.

Baladrón V, Ruiz-Hidalgo MJ, Bonvini E, Gubina E, Notario V, Laborda J.

Biochem Biophys Res Commun. 2002 Feb 22;291(2):193-204.


Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells.

Miscia S, Marchisio M, Grilli A, Di Valerio V, Centurione L, Sabatino G, Garaci F, Zauli G, Bonvini E, Di Baldassarre A.

Cell Growth Differ. 2002 Jan;13(1):13-8.


Membrane raft-dependent regulation of phospholipase Cgamma-1 activation in T lymphocytes.

Verí MC, DeBell KE, Seminario MC, DiBaldassarre A, Reischl I, Rawat R, Graham L, Noviello C, Rellahan BL, Miscia S, Wange RL, Bonvini E.

Mol Cell Biol. 2001 Oct;21(20):6939-50.


Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF.

Deb TB, Su L, Wong L, Bonvini E, Wells A, David M, Johnson GR.

J Biol Chem. 2001 May 4;276(18):15554-60. Epub 2001 Feb 5.


Differential effects of Cbl and 70Z/3 Cbl on T cell receptor-induced phospholipase Cgamma-1 activity.

Graham LJ, DeBell KE, Verí M, Stoica B, Mostowski H, Bonvini E, Rellahan B.

FEBS Lett. 2000 Mar 31;470(3):273-80.


Functional independence and interdependence of the Src homology domains of phospholipase C-gamma1 in B-cell receptor signal transduction.

DeBell KE, Stoica BA, Verí MC, Di Baldassarre A, Miscia S, Graham LJ, Rellahan BL, Ishiai M, Kurosaki T, Bonvini E.

Mol Cell Biol. 1999 Nov;19(11):7388-98.


Inefficient phospholipase C activation and reduced Lck expression characterize the signaling defect of umbilical cord T lymphocytes.

Miscia S, Di Baldassarre A, Sabatino G, Bonvini E, Rana RA, Vitale M, Di Valerio V, Manzoli FA.

J Immunol. 1999 Sep 1;163(5):2416-24.


Adipocyte differentiation is modulated by secreted delta-like (dlk) variants and requires the expression of membrane-associated dlk.

Garcés C, Ruiz-Hidalgo MJ, Bonvini E, Goldstein J, Laborda J.

Differentiation. 1999 Jan;64(2):103-14.


Sequences surrounding the Src-homology 3 domain of phospholipase Cgamma-1 increase the domain's association with Cbl.

Graham LJ, Stoica BA, Shapiro M, DeBell KE, Rellahan B, Laborda J, Bonvini E.

Biochem Biophys Res Commun. 1998 Aug 19;249(2):537-41.


The amino-terminal Src homology 2 domain of phospholipase C gamma 1 is essential for TCR-induced tyrosine phosphorylation of phospholipase C gamma 1.

Stoica B, DeBell KE, Graham L, Rellahan BL, Alava MA, Laborda J, Bonvini E.

J Immunol. 1998 Feb 1;160(3):1059-66.

Supplemental Content

Loading ...
Support Center